AnserBio

AnserBio Overview

AnserBio (previously ExoProTher Medical) is a biomedical start-up developing a novel approach to cancer treatment. The company targets the p53-based tumor suppression mechanism that is mutated in over 60% of cancers, including glioblastoma, colon, bladder, ovarian, and small cell lung cancers. It uses proprietary cell derived nano-particles to deliver healthy p53 and restore the body's natural tumor suppression function with minimal adverse side effects. The company is in the preclinical stage.

Cumulative Funding Raised Over Time ($)

Latest News

Jan 11, 2021 · en.globes.co.il

growth-positive

Fighting cancer from within

ExoProTher Medical, a company developing a new approach to cancer treatment, is closing a seed funding round. The company utilizes the p53 protein, which is recognized as a genome protector, to treat brain cancer. The treatment involves injecting animal protein in the form of nanoparticles. The company has completed a $1 million seed private placement and has raised about $700,000 to date. They are also running a crowdfunding campaign to raise additional funds. ExoProTher Medical plans to begin human trials for their product within three years.

Investment

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

HaTa'asiya St, Nesher, Israel

Photos & Videos

3 item(s)

AnserBio Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info